Abbott Laboratories Inc. announced the US FDA has approved its TactiCath - Sensor Enabled contact-force ablation catheter on Jan. 21.
The device is now indicated for cardiac electrophysiological mapping and the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used in conjunction with a compatible radio-frequency generator...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?